Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 24

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 24
---
shareholders. The price per Depositary Share at which we sell additional Depositary Shares, or securities convertible or exchangeable
into Depositary Shares, in future transactions may be higher or lower than the price per Depositary Shares paid by any investors in this
offering.

| 15 |

Sales of a substantial number of our Depositary Shares in the public markets, or the perception that such sales could occur, could cause our Depositary Share price to fall.

We may issue and sell additional
Depositary Shares in the public markets, including during this offering. As a result, a substantial number of our Depositary Shares may
be sold in the public market. Sales of a substantial number of our Depositary Shares in the public markets, including during this offering,
or the perception that such sales could occur, could depress the market price of our Depositary Shares and impair our ability to raise
capital through the sale of additional equity securities.

Because we do not currently intend to declare cash dividends on our Depositary Shares in the foreseeable future, Depositary Share holders must rely on appreciation of the value of our Depositary Shares for any return on their investment.

We have never paid cash dividends
on our Depositary Shares and do not plan to pay any cash dividends in the near future. We currently intend to retain all of our future
earnings, if any, to finance the operation, development and growth of our business. Furthermore, any future debt agreements may also preclude
us from paying or place restrictions on our ability to pay dividends. As a result, capital appreciation, if any, of our Depositary Shares
will be your sole source of gain with respect to your investment for the foreseeable future.

Because our management will have broad discretion and flexibility in how the net proceeds from this offering are used, our management may use the net proceeds in ways with which you disagree or which may not prove effective.

We currently intend to use
the net proceeds from this offering as discussed under “Use of Proceeds” in this prospectus. We have not allocated
specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant
discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard
to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net
proceeds are being used appropriately. It is possible that the net proceeds will be invested in